Bristol Myers Squibb CO
Forward trial catalysts linked to BMY
CSA tracks 5 forward catalysts for Bristol Myers Squibb CO across 5 assets, spanning Phase 3. The nearest is a readout expected Oct 19, 2026 (day precision). Confidence across its tracked catalysts breaks down as 5 medium. Tracked indications include Plaque Psoriasis, Psoriatic Arthritis, Systemic Lupus Erythematosus, and 8 more.
BMY in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, Bristol Myers Squibb CO has:
Forward catalysts by year
Every catalyst in the snapshot comes with its date, date confidence and source link.
23 trials behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| deucravacitinib | NCT04908202 | Phase 3 | Active, not recruiting | 2024-09-05 | Experimental | Bristol-Myers Squibb | Psoriatic Arthritis |
| deucravacitinib | NCT06143878 | Phase 3 | Active, not recruiting | 2024-09-17 | Active comparator | Janssen Research & Development, LLC | Plaque Psoriasis |
| deucravacitinib | NCT04908189 | Phase 3 | Active, not recruiting | 2024-11-07 | Experimental | Bristol-Myers Squibb | Psoriatic Arthritis |
| deucravacitinib | NCT06220604 | Phase 3 | Active, not recruiting | 2024-11-15 | Active comparator | Janssen Research & Development, LLC | Plaque Psoriasis |
| mezigdomide | NCT05552976 | Phase 3 | Active, not recruiting | 2026-09-28 | Experimental | Bristol-Myers Squibb | Relapsed or Refractory Multiple Myeloma |
| deucravacitinib | NCT05617677 catalyst | Phase 3 | Active, not recruiting | 2026-10-19 | Experimental | Bristol-Myers Squibb | Systemic Lupus Erythematosus |
| deucravacitinib | NCT05620407 | Phase 3 | Active, not recruiting | 2026-10-19 | Experimental | Bristol-Myers Squibb | Systemic Lupus Erythematosus |
| mezigdomide | NCT05519085 catalyst | Phase 3 | Recruiting | 2027-01-10 | Experimental | Celgene | Relapsed or Refractory Multiple Myeloma |
| repotrectinib | NCT06140836 catalyst | Phase 3 | Active, not recruiting | 2027-02-16 | Experimental | Bristol-Myers Squibb | Carcinoma, Non-Small-Cell Lung |
| iberdomide | NCT05558319 | Phase 3 | Recruiting | 2027-04 | Experimental | PETHEMA Foundation | Newly Diagnosed Multiple Myeloma |
| deucravacitinib | NCT07326813 | Phase 3 | Recruiting | 2027-07-12 | Active comparator | InventisBio Co., Ltd | Plaque Psoriasis |
| golcadomide | NCT06356129 catalyst | Phase 3 | Active, not recruiting | 2027-08-09 | Experimental | Celgene | Large B-cell Lymphoma |
| deucravacitinib | NCT07724366 | Phase 3 | Recruiting | 2027-09 | Active comparator | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Psoriasis |
| iberdomide | NCT04975997 catalyst | Phase 3 | Active, not recruiting | 2027-11-16 | Experimental | Celgene | Multiple Myeloma |
| golcadomide | NCT06911502 | Phase 3 | Recruiting | 2028-04-24 | Experimental | Celgene | Follicular Lymphoma |
| iberdomide | NCT06216158 | Phase 3 | Active, not recruiting | 2028-12 | Experimental | University of Heidelberg Medical Center | Multiple Myeloma |
| deucravacitinib | NCT04772079 | Phase 3 | Recruiting | 2029-01-01 | Experimental | Bristol-Myers Squibb | Plaque Psoriasis |
| iberdomide | NCT05827016 | Phase 3 | Active, not recruiting | 2029-03-15 | Experimental | Bristol-Myers Squibb | Multiple Myeloma |
| deucravacitinib | NCT06979453 | Phase 3 | Recruiting | 2029-10-12 | Active comparator | Bristol-Myers Squibb | Plaque Psoriasis |
| deucravacitinib | NCT06869551 | Phase 3 | Recruiting | 2030-03-06 | Experimental | Bristol-Myers Squibb | Juvenile Psoriatic Arthritis |
| deucravacitinib | NCT07791199 | Phase 3 | Not yet recruiting | 2030-10-31 | Experimental | Bristol-Myers Squibb | Systemic Lupus Erythematosus; Sjögren's Disease; Psoriasis; Psoriatic Arthritis |
| deucravacitinib | NCT07116967 | Phase 3 | Recruiting | 2031-01-16 | Experimental | Bristol-Myers Squibb | Plaque Psoriasis |
| iberdomide | NCT07624513 | Phase 3 | Not yet recruiting | 2033-10-01 | Experimental | Dana-Farber Cancer Institute | Multiple Myeloma |
Every trial the CSA sample links to BMY's tracked assets, including trials another sponsor runs and trials where the asset is not the experimental arm.
Conditions studied
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →